BACKGROUND Sustained virological response (SVR) and virological relapse maintain pivotal roles in the management of chronic hepatitis C (CHC); however, there is little data regarding the long-term outcomes of patients with CHC in China. OBJECTIVES We aimed to investigate the predictive factors of therapeutic effect and viral relapse in patients who achieved end-of-treatment response (ETR). ...

INTRODUCTION Hepatitis C virus (HCV) infection affects almost 3% of the world's population with the highest prevalence in Egypt (15%). The standard therapy; pegylated interferon (PEG-IFN) and ribavirin, is effective in only 60% of Egyptian patients; moreover it is costly, prolonged, and has severe side effects, so prediction of response is essential to reduce burden of unfavorable treatment. Se...

Hepatitis C virus (HCV) can be classified into seven distinct genotypes that are associated with differing pathologies and respond differently to antiviral therapy. In the UK, genotype 1 and 3 are present in approximately equal proportions. Chronic infection with HCV genotype 3 is associated with increased liver steatosis and reduced peripheral total cholesterol levels, which potentially influe...

Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated interferon α-2a and ribavirin (PegIFN/RBV) in treatment-naive patients in a prior study (SILEN-C1; M. S. Sulkowski et al., Hepatology 57:2143-2154, 2013, doi:10.1002/hep.26276), achieved sustained virologic response (SVR) rates of 72 to 84%. The...

HCV infection is a serious public health problem and a leading cause of chronic liver disease. It affects nearly 3% of the world's population with an associated high mortality. Egypt has the highest prevalence of HCV infection in the world (estimated at >10%). Peg-IFN-α and RBV are the most widely used therapy for HCV. Unfortunately, the rate of SVR is around 50%. In addition, it is expensive a...

results hla-drb1*07 (rr 5.3, p = 0.0008) and hla-drb1*08 (rr n.c. p = 0.0005) were significantly associated with the risk of pbc development. patients younger than 45 years had significantly higher alanine aminotransferase (p = 0.038) and alkaline phosphatase levels (p = 0.047) than older cases. in comparison to non-cc rs12979860, patients with cc rs12979860 genotype showed an early histologica...

conclusions examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg-ifn-α-2b plus rbv combination therapy for patients with hcv g1b even after the discovery of the il28 genotype as a potent predictive factor. objectives to re-examine the significance of lipoprotein profiles on virological response to peg-ifn plus rbv combination therapy in patients wit...

Hepatitis C virus (HCV) is a serious global health issue. Nearly 20% of HCV patients spontaneously clear the virus. While some studies have shown an association spontaneous clearance (SC) with interleukin (IL) 28B single-nucleotide polymorphisms (SNPs), others did not show such relationship. Thus, purpose present study was to investigate IL28B (12979860 SNP) SC infection. Upon initial screening...

Prevention of chronic hepatitis C (CHC) and its complications is based on antiviral therapy early detection reliable molecular markers in persons under risk. We investigated whether the methylation status RASSF1A p16 genes, alone or combination with host viral factors, affects response to pegylated interferon/ribavirin (PEG-IFN/RBV). Methylation-specific polymerase chain reaction (MSP) was used...

BACKGROUND AND OBJECTIVE The IL-28B rs12979860 CC and rs8099917 TT genotypes were proved to be predictor for pegylated-interferon (PEG-IFN)/ribavirin (RBV)-treated hepatitis C virus (HCV) patients. However, there were no identical conclusions on rs12980275 polymorphism. Our aim is to perform a meta-analysis in order to determine the association between rs12980275 polymorphism of IL28B and the s...